Back to Search

A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.

  • Protocol Number: 201807045
  • Principal Investigator: Schroeder, Mark
  • Cancer Types: Leukemia, Myeloma, and Hematologic

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.

Protocol Interventions

Ruxolitinib